# A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors

> **NCT05075564** · PHASE1 · COMPLETED · sponsor: **Elpiscience Biopharma, Ltd.** · enrollment: 8 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** Part 1 ES002023
- **DRUG:** Part 2 ES002023

## Key facts

- **NCT ID:** NCT05075564
- **Lead sponsor:** Elpiscience Biopharma, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-23
- **Primary completion:** 2022-10-13
- **Final completion:** 2022-10-13
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2025-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05075564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05075564, "A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05075564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*